Arax Advisory Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $174K | Buy |
3,104
+2,981
| +2,424% | +$174K | ﹤0.01% | 1150 |
|
|
2025
Q4 | $7.31K | Sell |
123
-103,211
| -100% | -$5.62M | ﹤0.01% | 2646 |
|
|
2025
Q3 | $5.6M | Buy |
103,334
+103,251
| +124,399% | +$5.9M | 0.08% | 205 |
|
|
2025
Q2 | $4.56K | Sell |
83
-31
| -27% | -$1.82K | ﹤0.01% | 2287 |
|
|
2025
Q1 | $8.06K | Buy |
114
+76
| +200% | +$5.11K | ﹤0.01% | 1625 |
|
|
2024
Q4 | $2.5K | Buy |
38
+26
| +217% | +$1.74K | ﹤0.01% | 1955 |
|
|
2024
Q3 | $844 | Buy |
12
+3
| +33% | +$251 | ﹤0.01% | 2308 |
|
|
2024
Q2 | $741 | Buy |
+9
| New | +$749 | ﹤0.01% | 2252 |
|
|
2023
Q4 | – | Sell |
-7
| Closed | -$620 | – | 1345 |
|
|
2023
Q3 | $620 | Sell |
7
-11
| -61% | -$979 | ﹤0.01% | 1216 |
|
|
2023
Q2 | $1.56K | Sell |
18
-1
| -5% | -$94 | ﹤0.01% | 1035 |
|
|
2023
Q1 | $1.85K | Hold |
19
| – | – | ﹤0.01% | 1000 |
|
|
2022
Q4 | $1.97K | Hold |
19
| – | – | ﹤0.01% | 943 |
|
|
2022
Q3 | $2K | Buy |
+19
| New | +$1.69K | ﹤0.01% | 939 |
|
|
2022
Q1 | – | Sell |
-15
| Closed | -$1K | – | 1154 |
|
|
2021
Q4 | $1K | Buy |
+15
| New | +$1.24K | ﹤0.01% | 973 |
|
|
2018
Q3 | – | Sell |
-237
| Closed | -$22K | – | 630 |
|
|
2018
Q2 | $22K | Buy |
237
+2
| +0.9% | +$175 | 0.01% | 288 |
|
|
2018
Q1 | $19K | Buy |
+235
| New | +$20.2K | 0.01% | 283 |
|
|
2017
Q3 | – | Sell |
-19
| Closed | -$2K | – | 469 |
|
|
2017
Q2 | $2K | Hold |
19
| – | – | ﹤0.01% | 439 |
|
|
2017
Q1 | $1K | Hold |
19
| – | – | ﹤0.01% | 480 |
|
|
2016
Q4 | $2K | Buy |
+19
| New | +$1.63K | ﹤0.01% | 456 |
|
Other funds holding BMRN
VCM
VPM
